tuberous sclerosis complex-associated refractory seizures
Neurology · 2017–2017
1decision
1medicine
1carried consumer input
2individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| everolimus Treatment of refractory seizures associated with tuberous sclerosis complex (TSC) in patients aged 2 years and older who have failed to be controlled… | Dec 2017 | Deferred | 2 individuals |
What the PBS pays
$23M in government benefit over 2024–25, across 24,537 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| everolimus | $23M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.